자료실

사이트 위치
HOME
자료실
HIV정보

HIV정보

[Science] 광범위 HIV 중화 항체발견으로 백신 개발 기대
작성자
홍기종
작성일
2009-09-06
조회
889

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target


1 Department of Immunology and Microbial Science, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
2 Design Lab, International AIDS Vaccine Initiative, New York, NY 11226, USA.
3 Theraclone Sciences, Seattle, WA 98104, USA.
4 Monogram Biosciences, Inc., South San Francisco, CA 94080, USA.
5 International AIDS Vaccine Initiative, New York, NY 10038, USA.
6 Department of Immunology and Microbial Science, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Techonology, and Harvard, Boston, MA 02114, USA.
 

* To whom correspondence should be addressed.
Sanjay K. Phogat , E-mail: SPhogat@iavi.org
Dennis R. Burton , E-mail: burton@scripps.edu
 

 

{dagger}These authors contributed equally to this work. 

{dagger}Protocol G Principal Investigators are listed at the end of the paper. 

Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1–infected individuals, define criticalepitopes for HIV vaccine design. Using a systematic approach, we have examined neutralization breadth in the sera of about 1800 HIV-1–infected individuals, primarily infected with non–clade B viruses, and have selected donors for monoclonal antibody (mAb) generation. We then used a high-throughput neutralization screen of antibody-containing culture supernatants from approximately 30,000 activated memory B cells from a clade A–infected African donor to isolate two potent mAbs that target a broadly neutralizing epitope. This epitope is preferentially expressed on trimeric Envelope protein and spans conserved regions of variable loops of the gp120 subunit. The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses.